Allergan Inc (AGN)
91.27USD
1 Aug 2013
$0.15 (+0.16%)
$91.12
$91.76
$92.92
$91.02
2,457,995
2,817,612
$116.45
$81.33
About
Overall
| Beta: | 0.84 |
| Market Cap (Mil.): | $27,008.01 |
| Shares Outstanding (Mil.): | 296.40 |
| Dividend: | 0.05 |
| Yield (%): | 0.22 |
Financials
| AGN | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 24.38 | 37.93 | 37.76 |
| EPS (TTM): | 3.74 | -- | -- |
| ROI: | 14.42 | 19.48 | 18.76 |
| ROE: | 21.09 | 20.17 | 19.59 |
Elan seeks bids from Allergan, Forest: sources
NEW YORK - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc , several people familiar with the matter said on Friday.
UPDATE 1-Elan seeks bids from Allergan, Forest -sources
NEW YORK, July 12 - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.
First-round bids for Elan due next week -sources
NEW YORK, July 12 - Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.
DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan
NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.
FDA draft guidance on generic eye drug push Allergen shares lower
WASHINGTON - Shares of Allergan Inc fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly.
Allergan delays drug that would rival Regeneron's Eylea
- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
Allergan delays eye drug, shares fall
- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.
BRIEF-Regeneron Pharma shares resume trading, up 16 percent
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval
BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3
NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3
Competitors
| Price | Change | |
|---|---|---|
| Alcon, Inc. (ACL.N) | -- | -- |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Medicis Pharmaceutical Corp (MRX.N) | -- | -- |
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Obagi Medical Products, Inc. (OMPI.OQ) | -- | -- |
| L'oreal S.A (OREP.PA) | €127.85 | +1.90 |
| Actavis Inc (ACT.N) | $135.78 | +1.51 |
| Astellas Pharma Inc (4503.T) | ¥5,340 | +90.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Trading Report for (AGN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

